LifeMD, Inc.
NASDAQ:LFMDMedical - Pharmaceuticals
-$0.16 today
- Market cap
- $82.17M
- Beta
- 1.99
- P/E (TTM)
- -13.8
- EPS (TTM)
- -$0.34
Volume 0.80M
Average 1.04M
LFMD Operating Income
Profit from core operations after operating expenses, before interest and taxes.
LifeMD, Inc.NASDAQ: LFMD
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income turns negative
Q1 FY2026 operating income was -$8.93M, compared with $2.54M a year earlier. Trailing-twelve-month operating income was -$12.9M.
Context
- Operating income amounted to 4.0% of revenue in FY2025, down 3.6 pp from a year earlier.
- Operating income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 5 analysts of -$24.66M (-221.5%) for the fiscal year ending Dec 2026, a slowdown from the +52.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$8.93M-713.4% QoQ
- Last fiscal yearDec 2025
- -$7.67M+52.5% YoY
- LTMMar 2026
- -$12.9M-91.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -451.1% | -674.2% | -223.1 pp |
| 1 year | +52.5% | -221.5% | -274.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (7.67M) USD
- Year-over-year change
- +52.5%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7.67M) | +52.5% |
| FY2024 | 2024-12-31 | (16.14M) | -11.4% |
| FY2023 | 2023-12-31 | (14.49M) | +66.7% |
| FY2022 | 2022-12-31 | (43.45M) | +20.0% |
| FY2021 | 2021-12-31 | (54.3M) | — |
Operating Income vs competitors
How LFMD compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -91.4% is the 9th highest of 10, against a peer median of +20.4%.
- Operating income amounts to 5.9% of revenue for LFMD, versus a peer median of 39.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $20.61M USD | +20.4% | -2.9% | 6.0% | |
| LTM Mar 2026 | $8.47M USD | +294.3% | — | 7.9% | |
| LTM Apr 2026 | -CA$3.21M CAD | -362.5% | — | 0.5% | |
| LTM Mar 2026 | -$12.9M USD | -91.4% | — | 5.9% | |
| LTM Mar 2026 | -$16.31M USD | +29.5% | — | 39.0% | |
| LTM Mar 2026 | -$17.69M USD | +0.1% | — | 7.9% | |
| LTM Mar 2026 | -$30.35M USD | +52.8% | — | 52.5% | |
| LTM Mar 2026 | -$35.65M USD | +28.2% | — | 44.8% | |
| LTM Mar 2026 | -$49.99M USD | +1.4% | — | 84.6% | |
| LTM Mar 2026 | -$86.7M USD | -23.7% | — | 213.0% | |
| Peer median (excluding LFMD) | — | +20.4% | -2.9% | 39.0% | |
Competitors are the stored peer set for LFMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 92.88M | 119.03M | 152.55M | 212.45M | 194.06M |
| Cost of Revenue | 18M | 18.67M | 18.9M | 24.07M | 39.29M |
| Gross Profit | 74.88M | 100.37M | 133.65M | 188.39M | 154.76M |
| Gross Margin | 80.6% | 84.3% | 87.6% | 88.7% | 79.8% |
| Research & Development | 948.16K | 2.97M | 6.06M | 9.51M | 7.35M |
| Selling, General & Admin | 122.08M | 125.33M | 128.15M | 175.68M | 144.01M |
| Operating Expenses | 129.18M | 143.81M | 148.14M | 204.53M | 162.43M |
| Depreciation & Amortization | 355.87K | 1.09M | 6.6M | 9.49M | 7.31M |
| EBITDA | (57.94M) | (38.6M) | (8.21M) | (6.65M) | (1.52M) |
| EBITDA Margin | -62.4% | -32.4% | -5.4% | -3.1% | -0.8% |
| Operating Income | (54.3M) | (43.45M) | (14.49M) | (16.14M) | (7.67M) |
| Operating Margin | -58.5% | -36.5% | -9.5% | -7.6% | -4.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.02M | 1.28M | 2.6M | 2.18M | 1.36M |
| Other Income / Expenses | (7.02M) | (1.21M) | (2.92M) | (2.18M) | (2.52M) |
| Income Before Tax | (61.32M) | (44.66M) | (17.41M) | (18.33M) | (10.19M) |
| Pre-Tax Margin | -66.0% | -37.5% | -11.4% | -8.6% | -5.2% |
| Income Tax Expense | 7.7K | 360.7K | 428K | 402K | 45.72K |
| Net Income | (60.9M) | (45.54M) | (20.6M) | (18.88M) | (7.11M) |
| Net Margin | -65.6% | -38.3% | -13.5% | -8.9% | -3.7% |
| EPS (Basic) | (2.27) | (1.57) | (0.70) | (0.53) | (0.23) |
| EPS (Diluted) | (2.27) | (1.57) | (0.70) | (0.53) | (0.23) |
| Weighted Avg Shares | 27.01M | 30.98M | 33.91M | 41.2M | 45.13M |
| Weighted Avg Shares (Diluted) | 27.01M | 30.98M | 33.91M | 41.2M | 45.13M |
LifeMD, Inc.
NASDAQ:LFMD
Intrinsic Alpha fair value
Locked
Current Price
$1.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.